- $1.21bn
- $1.19bn
- $174.54m
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 59 | 79.6 | 112 | 150 | 175 |
Cost of Revenue | |||||
Gross Profit | 42.1 | 58.2 | 79.9 | 103 | 117 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Total Operating Expenses | 45.2 | 73.5 | 388 | 162 | 163 |
Operating Profit | 13.9 | 6.07 | -276 | -12 | 11.9 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 13.1 | 4.49 | -282 | -12.2 | 11.5 |
Provision for Income Taxes | |||||
Net Income After Taxes | 12.7 | 4.06 | -282 | -13.3 | 9.25 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 12.7 | 4.06 | -171 | -7.65 | 6.03 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 12.7 | 4.06 | -188 | -8.61 | 9.25 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 0.112 | 0.036 | -2.25 | -0.101 | 0.071 |
Dividends per Share |